


# **ASTRAZENECA PLC**

## **Interim Financial Statements**

**30 September 2007**

Registered number 2723534

FRIDAY



\*A8GM9UBY\*

A12

02/11/2007

533

COMPANIES HOUSE

**PROFIT AND LOSS ACCOUNT**  
**for the nine months ended 30 September 2007**

		<b>30 September 2007 \$m</b>	<b>31 December 2006 \$m</b>
	<b>Notes</b>		
<b>Turnover</b>		-	-
Operating costs		(6)	(9)
<b>Operating loss</b>		(6)	(9)
Income from shares in subsidiary undertakings	2	9,411	681
Other income		1	-
<b>Profit on ordinary activities before interest</b>		9,406	672
Net interest	3	14	1
<b>Profit on ordinary activities before taxation</b>		9,420	673
Taxation		(9)	(21)
<b>Net profit for the period/year</b>		9,411	652

**STATEMENT OF TOTAL RECOGNISED GAINS AND LOSSES**  
**for the nine months ended 30 September 2007**

There are no gains or losses other than those reported above (2006 nil)

BALANCE SHEET

	Notes	30 September 2007 \$m	31 December 2006 \$m
<b>Fixed assets</b>			
Fixed asset investments	5	30,560	19,118
<b>Current assets</b>			
External debtors - other		3	9
Debtors – amounts owed by subsidiaries	6	6,832	1,382
		6,835	1,391
<b>Total assets</b>		37,395	20,509
<b>Creditors due within one year</b>			
Short-term borrowings	7	(5,320)	(7)
Other creditors		(67)	(12)
Amounts owed to subsidiaries		(10)	(14)
		(5,397)	(33)
<b>Net current assets</b>		1,438	1,358
<b>Total assets less current liabilities</b>		31,998	20,476
<b>Creditors due after more than one year</b>			
Loans	8	(8,931)	(1,030)
<b>Net assets</b>		23,067	19,446
<b>Capital and reserves</b>			
Called-up share capital	9	369	383
Share premium account	10	1,832	1,671
Capital redemption reserve	10	86	71
Other reserves	10	1,841	1,841
Profit and loss account	10	18,939	15,480
<b>Shareholders' funds - equity interests</b>	11	23,067	19,446

The interim financial statements on pages 1 to 6 were approved by the Board of Directors on 30 October 2007 and were signed on its behalf by



David R Brennan  
Director

**NOTES RELATING TO THE FINANCIAL STATEMENTS**

**1 Basis of presentation of financial information**

These AstraZeneca PLC interim financial statements are presented in accordance with the accounting policies set out in the AstraZeneca Annual Report and Form 20-F Information 2006

These financial statements do not constitute statutory accounts of the Company within the meaning of Section 240 of the Companies Act 1985. Statutory accounts for the year ended 31 December 2006 have been filed with the Registrar of Companies. The auditors' report on those accounts was unqualified and did not contain any statement under Section 237 of the Companies Act 1985.

**2 Income from shares in subsidiary undertakings**

	30 September 2007 \$m	31 December 2006 \$m
Dividends received from subsidiary undertakings	9,411	681

**3 Net interest**

	30 September 2007 \$m	31 December 2006 \$m
<b>Interest payable and similar charges</b>		
Payable to subsidiary undertakings	(15)	(20)
External interest payable	(274)	(41)
Net exchange and hedge losses	(7)	-
	(296)	(61)
<b>Interest receivable and similar income</b>		
Receivable from subsidiary undertakings	310	61
Net exchange gains	-	1
	310	62
<b>Net interest</b>	14	1

**NOTES RELATING TO THE FINANCIAL STATEMENTS (continued)**

**4 Dividends to shareholders**

	30 Sep 2007 per share	31 Dec 2006 per share	30 Sep 2007 \$m	31 Dec 2006 \$m
2 <sup>nd</sup> interim/final	\$1 230	\$0 920	1,885	1,453
1 <sup>st</sup> interim	\$0 520	\$0 490	773	764
	\$1 750	\$1 410	2,658	2,217

**5 Fixed asset investments**

	Shares \$m	Loans \$m	Total \$m
<b>Cost</b>			
At beginning of period	6,715	12,403	19,118
Additions	8,571	7,895	16,466
Exchange (Euro bond)	-	6	6
Repayment of loan	-	(5,030)	(5,030)
<b>At end of period</b>	15,286	15,274	30,560

On 26 July 2007, the Company increased its investment in AstraZeneca UK Limited by \$8,571m following that Company's recapitalisation

During September 2007, the Company issued \$7,895m bonds as part of the longer term debt structuring following the acquisition of MedImmune, Inc. This sum was on-lent to AstraZeneca Treasury Limited as long-term debt

**6 Debtors – amounts owed by subsidiaries**

	30 Sep 2007 \$m	31 Dec 2006 \$m
AstraZeneca Treasury Limited	6,740	1,296
AstraZeneca UK Limited	92	86
	6,832	1,382

The balance owed by AstraZeneca Treasury Limited at 30 September 2007 includes \$5,272m on-lent proceeds from commercial paper issues

**7 Short-term borrowings**

	30 Sep 2007 \$m	31 Dec 2006 \$m
Unclaimed dividends	19	7
External debt – commercial paper issues	5,301	-
	5,320	7

NOTES RELATING TO THE FINANCIAL STATEMENTS (continued)

8 Creditors due after more than one year

	Repayment dates	30 Sep 2007 \$m	31 Dec 2006 \$m
<b>Loans – owed to subsidiaries</b>			
US dollars			
7 2% loan	2023	282	282
<b>Loans – external</b>			
US dollars			
Floating rate note	2009	649	-
5 4% bond	2012	1,741	-
5 4% bond	2014	748	748
5 9% bond	2017	1,741	-
6 45% bond	2037	2,714	-
<b>Loans – external</b>			
Euros			
5 125% bond	2015	1,056	-
		8,931	1,030

All loans above are unsecured and are at fixed interest rates except the floating rate note

9 Called-up share capital

	Authorised	Allotted, called-up and fully paid	
	30 Sep 2007 \$m	30 Sep 2007 \$m	31 Dec 2006 \$m
Ordinary Shares (\$0 25 each)	369	369	383
Unissued Ordinary Shares (\$0 25 each)	231	-	-
Redeemable Preference Shares (£50,000)	-	-	-
	600	369	383

The movements in share capital during the period can be summarised as follows

	No. shares (millions)	\$m
At beginning of period	1,532	383
Issue of shares	4	1
Repurchase of shares	(62)	(15)
<b>At end of period</b>	<b>1,474</b>	<b>369</b>

**NOTES RELATING TO THE FINANCIAL STATEMENTS (continued)**

**10 Reserves**

	Share premium account \$m	Capital redemption reserve \$m	Other reserves \$m	Profit and loss account \$m	Total 30 Sep 2007 \$m	Total 31 Dec 2006 \$m
At beginning of period	1,671	71	1,841	15,480	19,063	23,778
Net profit for the period	-	-	-	9,411	9,411	652
Dividends	-	-	-	(2,658)	(2,658)	(2,217)
Share repurchase	-	15	-	(3,294)	(3,279)	(4,129)
Share premiums	161	-	-	-	161	979
At end of period	1,832	86	1,841	18,939	22,698	19,063
Distributable reserves at end of period	-	-	1,841	12,840	7,078	6,063

At 30 September 2007, \$6,099m (31 December 2006 \$11,129m) of the profit and loss account reserve was not available for distribution. The majority of this non-distributable amount relates to profit arising on the sale of Astra AB to a subsidiary in 1999, which becomes distributable as the underlying receivable is settled in cash. During the period \$5,030m of the profit was released by repayment. Included in other reserves is a special reserve of \$157m, arising on the redenomination of share capital in 1999.

**11 Reconciliation of movements in shareholders' funds**

	30 Sep 2007 \$m	31 Dec 2006 \$m
Net profit for the period/year	9,411	652
Dividends	(2,658)	(2,217)
	6,753	(1,565)
Issue of AstraZeneca Ordinary Shares	162	985
Repurchase of AstraZeneca Ordinary Shares	(3,294)	(4,147)
Net increase/(reduction) in shareholders' funds	3,621	(4,727)
Shareholders' funds at beginning of period/year	19,446	24,173
Shareholders' funds at end of period/year	23,067	19,446